Article
Gastroenterology & Hepatology
Marina Liso, Giulio Verna, Elisabetta Cavalcanti, Stefania De Santis, Raffaele Armentano, Angela Tafaro, Antonio Lippolis, Pietro Campiglia, Antonio Gasbarrini, Mauro Mastronardi, Theresa Torres Pizarro, Fabio Cominelli, Loris Riccardo Lopetuso, Marcello Chieppa
Summary: This study provides new insights and alternative approaches to treat ulcerative colitis (UC) patients. It suggests that anti-interleukin (IL)1 strategies, such as anakinra, may be a more effective therapeutic option for primary nonresponders to anti-tumor necrosis factor (TNF) therapy.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Cell Biology
Abigail R. Cannon, Esther H. Shim, Paulius Kuprys, Mashkoor A. Choudhry
Summary: Ulcerative colitis (UC) is a disease characterized by cycles of active flare and remission. Alcohol has been found to increase the severity of UC pathology. This study investigated the effects of alcohol on IL-22 expression and whether recombinant IL-22 or probiotic treatment could alleviate UC symptoms. The results showed that treatment with rIL-22 and Lactobacillus delbrueckii can attenuate UC exacerbation and increase IL-22 levels.
JOURNAL OF LEUKOCYTE BIOLOGY
(2022)
Article
Gastroenterology & Hepatology
Sigrid Lindh, Jonas Bengtsson, Jerzy Kaczynski
Summary: This retrospective study evaluates the effectiveness of biologic therapy for antibiotic-refractory pouchitis. The majority of patients responded well or partially to biologic therapy, especially those who were naive to previous treatment. Second-line treatment should be considered for patients who do not respond to first-line treatment. Caution should be exercised when using Infliximab for non-naive patients due to the risk of adverse reactions.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Agriculture, Multidisciplinary
Zecai Zhang, Yueqi Cui, Siyu Liu, Jiang Huang, Yu Liu, Yulong Zhou, Zhanbo Zhu
Summary: This study investigated the protective effects and potential mechanisms of zingerone (ZO) extracted from ginger on dextran sulfate sodium (DSS)-induced mouse ulcerative colitis (UC). The results showed that ZO alleviated weight loss, reduced disease activity index scores, and improved pathological changes in colon tissue. Mechanism analysis revealed that ZO inhibited the activation of the nuclear factor-kappa B pathway and regulated peroxisome proliferator-activated receptor gamma (PPAR gamma) expression. The findings suggest that ZO supplementation may be a new dietary strategy for UC treatment.
JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
(2022)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, John K. Marshall, Jean-Frederic Colombel, Parambir S. Dulai, Walter Reinisch
Summary: For patients with moderate to severe biologic naive UC, infliximab and vedolizumab have similar efficacy in improving clinical symptoms, but infliximab has higher rates of corticosteroid-free clinical remission (CR) and endoscopic remission (ER) after 1 year of treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Chaparro
Summary: The de-escalation of biologic therapy in inflammatory bowel disease (IBD) carries risks and uncertainties and should be tailored to individual patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Pharmacology & Pharmacy
Riccardo Capecchi, Paola Migliorini, Federico Zanzi, Simona Maltinti, Ilaria Puxeddu, Nicola de Bortoli, Massimo Bellini, Francesco Costa, Santino Marchi, Lorenzo Bertani
Summary: The study demonstrated a correlation between Ig glycosylation and disease activity in UC patients, suggesting a potential role for lectin-selected Ig in predicting therapeutic effectiveness. If confirmed, Ig glycosylation could serve as a biomarker in UC.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Jana Stofilova, Monika Kvakova, Anna Kamlarova, Emilia Hijova, Izabela Bertkova, Zuzana Gul'asova
Summary: There is a need for new therapies for ulcerative colitis, as many patients are unresponsive to available treatments. Strategies targeting dysbiosis of gut microbiota have been tested, but the effectiveness of conventional probiotics varies. New candidates for next-generation probiotics could provide more targeted treatment options.
Article
Microbiology
Cristiano Pagnini, Maria Carla Di Paolo, Riccardo Urgesi, Lorella Pallotta, Gianfranco Fanello, Maria Giovanna Graziani, Gianfranco Delle Fave
Summary: This study aimed to investigate the clinical efficacy and safety of LGG administration in UC patients with mild-moderate disease activity. The results showed that monotherapy with LGG is safe and effective for inducing remission in UC patients.
Article
Medicine, Research & Experimental
Jingyi Hu, Yiheng Tong, Zhaofeng Shen, Yanan Li, Cheng Cheng, Ryan Au, Feng Xu, Yajun Liu, Lei Zhu, Hong Shen
Summary: Ulcerative colitis (UC) is a chronic inflammatory disease of the intestine, and dysbiosis of gut microbiota is one of its main pathogenic mechanisms. This study found that Gegen Qinlian decoction (GD) could inhibit the expansion of pathogenic Escherichia coli (E. coli) by activating PPAR-gamma signaling pathway, which contributes to the improvement of UC symptoms.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Qing-yu Cui, Xiao-ying Tian, Xi Liang, Zhe Zhang, Rui Wang, Yu Zhou, Hua-xi Yi, Pi-min Gong, Kai Lin, Tong-jie Liu, Lan-wei Zhang
Summary: This study aimed to identify probiotics with the potential to alleviate inflammatory bowel disease and elucidate their mechanism of action. Two strains of Bifidobacterium bifidum, FL-276.1 and FL-228.1, were found to be the most effective in improving body weight loss, colon shortening, and intestinal barrier disruption in mice. It was further discovered that these strains activated the aryl hydrocarbon receptor (AhR) in the intestine, potentially contributing to their anti-inflammatory properties.
Article
Gastroenterology & Hepatology
Lujain Maasfeh, Anetta Hartlova, Stefan Isaksson, Johanna Sundin, Georgios Mavroudis, Otto Savolainen, Hans Strid, Lena Ohman, Maria K. Magnusson
Summary: Fecal luminal factors from healthy donors can down-regulate signaling pathways in macrophages and influence their function, while those from UC patients in remission have a weaker effect on macrophages. Metabolomic analysis revealed differential fecal metabolite composition between healthy individuals and UC patients in remission. This suggests that UC patients in remission may lack the necessary signals to condition macrophages towards a hyporesponsive and tolerogenic phenotype, making them vulnerable to relapse.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Jeffrey A. Berinstein, Jessica L. Sheehan, Michael Dias, Elliot M. Berinstein, Calen A. Steiner, Laura A. Johnson, Randolph E. Regal, John I. Allen, Kelly C. Cushing, Ryan W. Stidham, Shrinivas Bishu, Jami A. R. Kinnucan, Shirley A. Cohen-Mekelburg, Akbar K. Waljee, Peter D. R. Higgins
Summary: The study suggests that tofacitinib with concomitant intravenous corticosteroids may reduce the risk of colectomy in ASUC patients, especially with a dosage of 10 mg three times daily. Rates of complications and steroid dependence were similar between the tofacitinib group and controls. Prospective trials are needed to further investigate the safety and optimal dosing of tofacitinib in ASUC patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Kevin Baker, Charlotte O'Donnell, Maura Bendix, Samuel Keogh, James Byrne, Michael O'Riordain, Peter Neary, Aileen Houston, Elizabeth Brint
Summary: IL-36 cytokines play a significant role in the pathogenesis of colon cancer by activating pro-tumorigenic phenotypes and inducing pro-inflammatory response. Targeting IL-36R signaling may be a useful therapy for colorectal cancer patients with IL-36R(+) tumor cells.
Article
Geriatrics & Gerontology
Marco Vincenzo Lenti, Nicola Aronico, Paolo Giuffrida, Stefania Costa, Martina Costetti, Clarissa Musacchio, Luca Pastorelli, Caterina Mengoli, Federica Borrelli de Andreis, Sara Cococcia, Carmine Tinelli, Catherine Klersy, Maurizio Vecchi, Alberto Pilotto, Antonio Di Sabatino
Summary: The Multidimensional Prognostic Index (MPI) can predict mortality and is associated with a higher risk of developing diverticular disease (DD) complications in older patients. Patients with higher MPI groups have a greater likelihood of developing DD complications.
Article
Medicine, Research & Experimental
Stefano Mazza, Nicole Piazza O. Sed, Francesco Simone Conforti, Alberto Fasci, Alessandro Rimondi, Beatrice Marinoni, Valentina Casini, Chiara Ricci, Francesca Munari, Lorena Pirola, Pietro Invernizzi, Carlo Girelli, Guido Lupinacci, Luca Pastorelli, Flaminia Cavallaro, Luca Ferraris, Alice Colucci, Arnaldo Amato, Gian Eugenio Tontini, Maurizio Vecchi, Gionata Fiorino, Flavio Caprioli
Summary: A study in Italy evaluated the safety and efficacy of double-switching from originator IFX to CT-P13 and subsequently to SB2 in patients with IBD. Results showed that the double switch was associated with high continuation rates of IFX therapy and high clinical remission rates, without significant differences in safety and efficacy compared to single-switching.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2022)
Article
Gastroenterology & Hepatology
Stefanos Bonovas, Claudia Pansieri, Daniele Piovani, Fabio Salvatore Macaluso, Ambrogio Orlando, Stefano Festa, Claudio Papi, Daniela Pugliese, Alessandro Armuzzi, Gionata Fiorinof, Massimo Claudio Fantinig, Flavio Capri, Marco Dapernok
Summary: The management of moderate to severe ulcerative colitis has changed significantly with the approval of new drugs, including biologicals and small molecules. The Italian Group for the Study of Inflammatory Bowel Disease has developed clinical guidelines based on the GRADE methodology to guide treatment decisions.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Gastroenterology & Hepatology
Xianyong Gui, Alina Bazarova, Rocio Del Amor, Michael Vieth, Gert de Hertogh, Vincenzo Villanacci, Davide Zardo, Tommaso Lorenzo Parigi, Elin Synnove Royset, Uday N. Shivaji, Melissa Anna Teresa Monica, Giulio Mandelli, Pradeep Bhandari, Silvio Danese, Jose G. Ferraz, Bu'Hussain Hayee, Mark Lazarev, Adolfo Parra-Blanco, Luca Pastorelli, Remo Panaccione, Timo Rath, Gian Eugenio Tontini, Ralf Kiesslich, Raf Bisschops, Enrico Grisan, Valery Naranjo, Subrata Ghosh, Marietta Iacucci
Summary: Histological remission is emerging as a key treatment target in UC, and the development of a simple histological index PHRI showed high correlation with endoscopic activity and clinical outcomes. A deep learning AI system based on PHRI accurately predicted histological remission and differentiated active from quiescent UC, with promising sensitivity, specificity, and accuracy results.
Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Federica Crispino, Nicolo Mezzina, Fabiana Castiglione, Gionata Fiorino, Lucrezia Laterza, Anna Viola, Lorenzo Bertani, Flavio Caprioli, Maria Cappello, Brigida Barberio, Chiara Ricci, Paola Balestrieri, Marco Daperno, Dario Pluchino, Fernando Rizzello, Maria Lia Scribano, Renato Sablich, Luca Pastorelli, Francesco Manguso, Angela Variola, Antonio Di Sario, Laurino Grossi, Alessandro Armuzzi
Summary: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients. No significant difference in effectiveness was observed between elderly and nonelderly CD patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, Research & Experimental
Laura Francesca Pisani, Gianeugenio Tontini, Maurizio Vecchi, Giorgio Alberto Croci, Luca Pastorelli
Summary: This study investigated the potential inflammatory pathways involved in the development of microscopic colitis (MC). The findings suggest that an impairment of the non-canonical nuclear transcription factor kappa B (NF-kB) pathway is involved in the development of MC.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Olga Maria Nardone, Alina Bazarova, Pradeep Bhandari, Rosanna Cannatelli, Marco Daperno, Jose Ferraz, Martin Goetz, Xianyong Gui, Bu Hayee, Gert De Hertogh, Mark Lazarev, Ji Li, Adolfo Parra-Blanco, Luca Pastorelli, Remo Panaccione, Vincenzo Occhipinti, Timo Rath, Samuel C. L. Smith, Uday N. Shivaji, Gian Eugenio Tontini, Michael Vieth, Vincenzo Villanacci, Davide Zardo, Raf Bisschops, Ralf Kiesslich, Subrata Ghosh, Marietta Iacucci
Summary: This study investigated the importance of combined endoscopic-histologic remission in predicting clinical outcomes in ulcerative colitis patients. The results showed that at 12 months, there was no significant difference in predicting specified clinical outcomes between endoscopic remission alone and combined endoscopic-histologic remission, but UCEIS combined with histology showed a significant advantage. More studies with specific therapeutic interventions are needed to confirm these findings.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2022)
Article
Medicine, General & Internal
Francesca Ferretti, Maria Camilla Monico, Rosanna Cannatelli, Stefania Carmagnola, Marco Vincenzo Lenti, Antonio Di Sabatino, Francesco Conforti, Luca Pastorelli, Flavio Caprioli, Cristina Bezzio, Simone Saibeni, Stefano Mazza, Maurizio Vecchi, Giovanni Maconi, Sandro Ardizzone
Summary: This study suggests that the type of biologic treatment may affect the risk of developing extra-intestinal manifestations in patients with inflammatory bowel disease. There is a slightly higher risk in patients on gut-selective therapies, but the clinical course is similar in both groups.
FRONTIERS IN MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Vincenzo Occhipinti, Paola Soriani, Sara Vavassori, Maria Laura Annunziata, Francesco Bagolini, Flaminia Cavallaro, Pavlos Lagoussis, Valentina Milani, Emanuele Rondonotti, Luisa Spina, Maurizio Vecchi, Luca Pastorelli, Gian Eugenio Tontini
Summary: Bowel preparation is crucial for colonoscopy completeness and lesions detection. Identification of preparation-specific risk factors for inadequate bowel preparation may lead to a personalized prescription of cleansing products to refine patients' tolerance and improve endoscopic outcomes.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Giovanni Cataletti, Fabrizio Santagata, Luca Pastorelli, Pier Maria Battezzati
Summary: Drug-induced liver injury (DILI) is the leading cause of acute liver failure in high-income countries, and acute cholestasis is a common hepatotoxicity caused by drugs. We described an uncommon case of DILI that occurred after 22 months of azathioprine administration, suggesting that long-term use of azathioprine may lead to liver injury.
Article
Gastroenterology & Hepatology
Marietta Iacucci, Tommaso Lorenzo Parigi, Rocio Del Amor, Pablo Meseguer, Giulio Mandelli, Anna Bozzola, Alina Bazarova, Pradeep Bhandari, Raf Bisschops, Silvio Danese, Gert De Hertogh, Jose G. Ferraz, Martin Goetz, Enrico Grisan, Xianyong Gui, Bu Hayee, Ralf Kiesslich, Mark Lazarey, Remo Panaccione, Adolfo Parra-Blanco, Luca Pastorelli, Timo Rath, Elin S. Royset, Gian Eugenio Tontini, Michael Vieth, Davide Zardo, Subrata Ghosh, Valery Naranjo, Vincenzo Villanacci
Summary: An artificial intelligence computer-aided diagnosis system was developed and validated to evaluate UC biopsies and predict prognosis. The system showed high accuracy and sensitivity in assessing biopsy results and predicting outcomes.
Article
Medicine, General & Internal
Olga Maria Nardone, Giovanni Marasco, Loris Riccardo Lopetuso, Giammarco Mocci, Luca Pastorelli, Carlo Petruzzellis, Franco Scaldaferri
Summary: This study investigated the use of mesalazine in the clinical practice of young gastroenterologists. The results showed that there were significant differences in the use of mesalazine between non-dedicated and IBD physicians, especially in the management of moderate-severe ulcerative colitis. It was also observed that non-IBD physicians were less likely to prescribe mesalazine for colorectal cancer chemoprevention.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Marco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, Rachele Ciccocioppo, Daniela Pugliese, Luca Pastorelli, Gionata Fiorino, Edoardo Savarino, Flavio Andrea Caprioli, Sandro Ardizzone, Massimo Claudio Fantini, Gian Eugenio Tontini, Ambrogio Orlando, Gianluca Matteo Sampietro, Giacomo Carlo Sturniolo, Giovanni Monteleone, Maurizio Vecchi, Anna Kohn, Marco Daperno, Renata D'Inca, Gino Roberto Corazza, Antonio Di Sabatino
Summary: IBD is a complex immune-mediated disorder affecting the gastrointestinal and systemic manifestations, leading to poor quality of life and negative health outcomes. A comprehensive management considering both biological and non-biological factors is necessary. The 4P medicine framework, including personalization, prediction, prevention, and participation is useful for tailoring interventions in IBD patients.
FRONTIERS IN MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Cristina Bezzio, Marta Vernero, Stefania Costa, Alessandro Armuzzi, Gionata Fiorino, Sandro Ardizzone, Jenny Roselli, Sonia Carparelli, Ambrogio Orlando, Flavio Andrea Caprioli, Fabiana Castiglione, Chiara Vigano, Davide Ribaldone, Fabiana Zingone, Rita Monterubbianesi, Nicola Imperatore, Stefano Festa, Marco Daperno, Ludovica Scucchi, Antonio Ferronato, Luca Pastorelli, Eleonora Alimenti, Paola Balestrieri, Chiara Ricci, Maria Cappello, Carla Felice, Francesca Coppini, Patrizia Alvisi, Imma Di Luna, Viviana Gerardi, Angela Variola, Silvia Mazzuoli, Marco Vincenzo Lenti, Simone Saibeni
Summary: This study compared the characteristics and outcomes of inflammatory bowel disease (IBD) patients with SARS-CoV-2 infection between the two pandemic waves in Italy. The patients in the first wave were older, more likely to have ulcerative colitis and comorbidities, and resided more frequently in Northern Italy. The rates of negative outcomes, such as pneumonia, hospital admission, ventilatory support, and death, were significantly higher in the first wave compared to the second wave.
BMC GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Chiara Vigano, Andrea Palermo, Giacomo Mulinacci, Lorena Pirola, Alessandra Losco, Gianmichele Meucci, Simone Saibeni, Luca Pastorelli, Arnaldo Amato, Mario Gatti, Claudio Cortelezzi, Antonio Di Sabatino, Daniela Morganti, Francesca Boni, Gianalberto Grasso, Giovanni Casella, Valentina Casini, Flavio Andrea Caprioli, Maurizio Vecchi, Cristina Bezzio, Irene Bergna, Franco Radaelli, Caterina Mengoli, Sara Massironi
Summary: Disease-related malnutrition (DRM) is prevalent in inflammatory bowel disease (IBD) patients, with a rate of 23% and no significant difference between Crohn's disease and ulcerative colitis. DRM is associated with higher hospitalization rate, more frequent use of systemic steroids, lower levels of hemoglobin, albumin, prealbumin, and higher levels of C-reactive protein. Low BMI, current hospitalization, and hospitalization in the previous month are significantly associated with DRM.
INFLAMMATORY BOWEL DISEASES
(2023)
